MapLight Therapeutics (MPLT) Analyst & Key Data

Analyst Consensus

Buy23 analysts

Buy

Updated Sep 12, 2026

Total Analysts23

Buy

5

Hold

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$13.00

Median Target+168.23%

$34.87

Potential upside vs current price

DCF Value-92.85%

$0.93

Potential downside vs current price

Current Stock Price

$13.00

Median Target+168.23%

$34.87

Potential upside vs current price

DCF Value-92.85%

$0.93

Potential downside vs current price

Analyst Consensus

Buy23 analysts

Buy

Updated Sep 12, 2026

Total Analysts23

Buy

5

Hold

2

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$13.00

Median Target+168.23%

$34.87

Potential upside vs current price

DCF Value-92.85%

$0.93

Potential downside vs current price

Current Stock Price

$13.00

Median Target+168.23%

$34.87

Potential upside vs current price

DCF Value-92.85%

$0.93

Potential downside vs current price

MapLight Therapeutics, Inc.